La catena delle opzioni mostra i dati chiave delle opzioni azionarie di C4 Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per C4 Therapeutics..

C4 Therapeutics (NASDAQ:CCCC) Azioni, Catena delle Opzioni

C4 Therapeutics

C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.

C4 Therapeutics Inc

C4 Therapeutics (CCCC) has provided an update. In a recent corporate shake-up, the Company has announced Dr. Fawell's appointment to the Board whil...

C4 Therapeutics Announces Board Changes and Strategic Shift

In a report released today, Bradley Canino from Stifel Nicolaus maintained a Buy rating on C4 Therapeutics (CCCC – Research Report), with a price t...

C4 Therapeutics (CCCC) Gets a Buy from Stifel Nicolaus

Derek Archila, an analyst from Wells Fargo, maintained the Hold rating on C4 Therapeutics (CCCC – Research Report). The associated price target is ...

Hold Rating on C4 Therapeutics Amid Early-Stage Drug Development and Market Caution

Terence Flynn, an analyst from Morgan Stanley, maintained the Hold rating on C4 Therapeutics (CCCC – Research Report). The associated price target ...

Cautious Hold Rating on C4 Therapeutics Amid Modest Efficacy and Pending Data

Stifel Nicolaus analyst Bradley Canino maintained a Buy rating on C4 Therapeutics (CCCC – Research Report) today and set a price target of $14.00. ...

Stifel Nicolaus Keeps Their Buy Rating on C4 Therapeutics (CCCC)

C4 Therapeutics ( ($CCCC) ) has shared an update. C4 Therapeutics has appointed Paige Mahaney, Ph.D., as the new Chief Scientific Officer, succeedi...

C4 Therapeutics Appoints New Chief Scientific Officer

C4 Therapeutics GAAP EPS of -$0.35 beats by $0.05, revenue of $15.36M beats by $10.76M

17:30 EDT C4 Therapeutics (CCCC) files $400M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving br...

C4 Therapeutics files $400M mixed securities shelf

17:29 EDT C4 Therapeutics (CCCC) files to sell 4.87M shares of common stock for holders Published first on TheFly – the ultimate source for real-ti...

C4 Therapeutics files to sell 4.87M shares of common stock for holders

C4 Therapeutics, Inc. ( ($CCCC) ) has released its Q3 earnings. Here is a breakdown of the information C4 Therapeutics, Inc. presented to its inves...

C4 Therapeutics Advances in Protein Degradation Therapy

CCCC

News

Press Releases

C4 Therapeutics to Participate in Upcoming September Investor Conferences

Management

C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024

C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen

Health Care

General

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Markets

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit

C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

Earnings

C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Absci

Akebia Therapeutics

Altimmune

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics

Aura Biosciences

Emergent BioSolutions

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Foghorn Therapeutics

GRAIL

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharma

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

MeiraGTx Hldgs

Organogenesis Hldgs

Prime Medicine

Regenxbio

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Sage Therapeutics

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

Tevogen Bio Holdings

Valneva

Verve Therapeutics

Voyager Therapeutics, Inc. - Common Stock

Comments

C4 Therapeutics

C4 Therapeutics (CCCC) Opzioni

C4 Therapeutics (NASDAQ:CCCC) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO